Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
PMID: 31189581
2019
Journal of clinical microbiology
Discussion: Currently, the well-known classical NA resistance mutations are mainly located in domains B, C, D, and E, such as rtI169T, rtA181T/V, and rtT184A/C/F/G/I/L/M (located in domain B), rtS202C/G/I and rtM204I/V/S (located in domain C), rtN236T (located in domain D), and rtM250I/L/V (located in domain E).
Discussion: In this study, except rtA181T,
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Introduction: These two categories are known as classical mutations, which include: (i) M204I/V mutation, which associates with LAM or LDT resistance; (ii) N236T or A181T/V mutations, which associate with ADV res
Discussion: reported that an combined mutation pattern of L80M, L180M, M204V/I, A200V, F221Y, S223A, T184A/L, R153Q, and rtV191I was detected at the time of virological and biochemical breakthrough emerged during TDF monotherapy, following an unsuccessful LAM, ETV and ADV sequential or combined treatment.
[Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.
[HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Abstract: Primary/secondary drug mutations (rtM204I/V, rtI169S, rtL180M, rtT184L, rtA194V, rtM204I/rtL91I, rtQ149K, rtQ215H/S, rtN238D) were detected in 38 (45.2%) of the patients.
Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.
PMID: 30906435
2019
Experimental and therapeutic medicine
Discussion: Other mutations, including rtV84M, rtN118H/D/T, rtI169T, rtT184A/L/S, rtV191I, rtV207I/M, rtS213T, rtQ215P/S/H, rtI233L, rtP237H/T and rtS202G, which have been previous
Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
Discussion: identified ETV-resistance features in the mutants rtL180M+M204V (LAMr), LAMr+rtT184L, LAMr+rtS202G, LAMr+rtM250V, and LAMr+rtT184G+rtS202I, showing they had 27, 246, 402, 1028, and >1333-fold respective decreases in drug susceptibility when compared to the wild-type strain.
Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
Result: Phenotypic analysis of the remaining 12 of 15 identified novel emergent substitutions indicated a reduced susceptibility to ETV (>758-fold greater than WT; Table 2) due to the presence of high-level ETVr HBV RT substitutions rt Discussion: Previous findings have suggested that substitutions (e.g., rtI169T) at this amino acid position may act in a compensatory manner in ETVr HBV.( 14 ) Our data suggest that HBV rt169V may also have an adaptive role in ETVr HBV, specifically during the emergence of rtT184L with rtL180M+rtM204V in patients with virologic failure infected with genotype C HBV.
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.
Introduction: Virological breakthrough on TDF therapy has been reported in two patients harbouring rtS78T/sC69 mutations, and in another patient with multi-site polymerase mutations; rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and
HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.
Introduction: According to several clinical practice guidelines and authoritative reviews, NUCr substitutions can be classified into two categories: primary NUCr substitutions at 8 codons (rtI169T, rt
Introduction: Resistance to ETV needs a combination of substitutions of rtM204I/V and rtL180M plus one of the following substitutions: rtI169T, rtT184A/C/F/G/I/L/M/S, rtS202C/G/I or rtM250I/L/V.
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
HBV mutation literature information.
PMID: 
2019
Journal of clinical microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT